303 related articles for article (PubMed ID: 22915320)
1. ROS1 receptor tyrosine kinase, a druggable target, is frequently overexpressed in non-small cell lung carcinomas via genetic and epigenetic mechanisms.
Lee HJ; Seol HS; Kim JY; Chun SM; Suh YA; Park YS; Kim SW; Choi CM; Park SI; Kim DK; Kim YH; Jang SJ
Ann Surg Oncol; 2013 Jan; 20(1):200-8. PubMed ID: 22915320
[TBL] [Abstract][Full Text] [Related]
2. Analysis of receptor tyrosine kinase ROS1-positive tumors in non-small cell lung cancer: identification of a FIG-ROS1 fusion.
Rimkunas VM; Crosby KE; Li D; Hu Y; Kelly ME; Gu TL; Mack JS; Silver MR; Zhou X; Haack H
Clin Cancer Res; 2012 Aug; 18(16):4449-57. PubMed ID: 22661537
[TBL] [Abstract][Full Text] [Related]
3. ROS1-rearranged lung cancer: a clinicopathologic and molecular study of 15 surgical cases.
Yoshida A; Kohno T; Tsuta K; Wakai S; Arai Y; Shimada Y; Asamura H; Furuta K; Shibata T; Tsuda H
Am J Surg Pathol; 2013 Apr; 37(4):554-62. PubMed ID: 23426121
[TBL] [Abstract][Full Text] [Related]
4. ROS1 expression and translocations in non-small-cell lung cancer: clinicopathological analysis of 1478 cases.
Warth A; Muley T; Dienemann H; Goeppert B; Stenzinger A; Schnabel PA; Schirmacher P; Penzel R; Weichert W
Histopathology; 2014 Aug; 65(2):187-94. PubMed ID: 24456475
[TBL] [Abstract][Full Text] [Related]
5. Identification of ROS1 rearrangement in gastric adenocarcinoma.
Lee J; Lee SE; Kang SY; Do IG; Lee S; Ha SY; Cho J; Kang WK; Jang J; Ou SH; Kim KM
Cancer; 2013 May; 119(9):1627-35. PubMed ID: 23400546
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of STAT3 expression and its correlation with chemoresistance of non-small cell lung cancer cells.
Yin Z; Zhang Y; Li Y; Lv T; Liu J; Wang X
Acta Histochem; 2012 Feb; 114(2):151-8. PubMed ID: 21549414
[TBL] [Abstract][Full Text] [Related]
7. MiR-760 suppresses non-small cell lung cancer proliferation and metastasis by targeting ROS1.
Yan C; Zhang W; Shi X; Zheng J; Jin X; Huo J
Environ Sci Pollut Res Int; 2018 Jul; 25(19):18385-18391. PubMed ID: 29372517
[TBL] [Abstract][Full Text] [Related]
8. The transmembrane adaptor Cbp/PAG1 controls the malignant potential of human non-small cell lung cancers that have c-src upregulation.
Kanou T; Oneyama C; Kawahara K; Okimura A; Ohta M; Ikeda N; Shintani Y; Okumura M; Okada M
Mol Cancer Res; 2011 Jan; 9(1):103-14. PubMed ID: 21156787
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of MCM7 expression in the bronchial brushings of patients with non-small cell lung cancer (NSCLC).
Liu YZ; Jiang YY; Hao JJ; Lu SS; Zhang TT; Shang L; Cao J; Song X; Wang BS; Cai Y; Zhan QM; Wang MR
Lung Cancer; 2012 Jul; 77(1):176-82. PubMed ID: 22456526
[TBL] [Abstract][Full Text] [Related]
10. Activated epidermal growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell lung cancer.
Haura EB; Zheng Z; Song L; Cantor A; Bepler G
Clin Cancer Res; 2005 Dec; 11(23):8288-94. PubMed ID: 16322287
[TBL] [Abstract][Full Text] [Related]
11. ROS1 as a 'druggable' receptor tyrosine kinase: lessons learned from inhibiting the ALK pathway.
Ou SH; Tan J; Yen Y; Soo RA
Expert Rev Anticancer Ther; 2012 Apr; 12(4):447-56. PubMed ID: 22500682
[TBL] [Abstract][Full Text] [Related]
12. Comparison of detection methods and follow-up study on the tyrosine kinase inhibitors therapy in non-small cell lung cancer patients with ROS1 fusion rearrangement.
Wu J; Lin Y; He X; Yang H; He P; Fu X; Li G; Gu X
BMC Cancer; 2016 Aug; 16():599. PubMed ID: 27488371
[TBL] [Abstract][Full Text] [Related]
13. Clinicopathologic analysis of ROS1-rearranged non-small-cell lung cancer and proposal of a diagnostic algorithm.
Go H; Kim DW; Kim D; Keam B; Kim TM; Lee SH; Heo DS; Bang YJ; Chung DH
J Thorac Oncol; 2013 Nov; 8(11):1445-50. PubMed ID: 24128715
[TBL] [Abstract][Full Text] [Related]
14. STAT3 activation and aberrant ligand-dependent sonic hedgehog signaling in human pulmonary adenocarcinoma.
Yang Q; Shen SS; Zhou S; Ni J; Chen D; Wang G; Li Y
Exp Mol Pathol; 2012 Oct; 93(2):227-36. PubMed ID: 22554932
[TBL] [Abstract][Full Text] [Related]
15. Frequent aerogenous spread with decreased E-cadherin expression of ROS1-rearranged lung cancer predicts poor disease-free survival.
Jin Y; Sun PL; Park SY; Kim H; Park E; Kim G; Cho S; Kim K; Lee CT; Chung JH
Lung Cancer; 2015 Sep; 89(3):343-9. PubMed ID: 26149475
[TBL] [Abstract][Full Text] [Related]
16. Hypermethylation of the GATA genes in lung cancer.
Guo M; Akiyama Y; House MG; Hooker CM; Heath E; Gabrielson E; Yang SC; Han Y; Baylin SB; Herman JG; Brock MV
Clin Cancer Res; 2004 Dec; 10(23):7917-24. PubMed ID: 15585625
[TBL] [Abstract][Full Text] [Related]
17. In vitro and in vivo expressions of transforming growth factor-alpha and tyrosine kinase receptors in human non-small-cell lung carcinomas.
Liu C; Tsao MS
Am J Pathol; 1993 Apr; 142(4):1155-62. PubMed ID: 8097369
[TBL] [Abstract][Full Text] [Related]
18. Epigenetic modulation of tumor suppressor CCAAT/enhancer binding protein alpha activity in lung cancer.
Tada Y; Brena RM; Hackanson B; Morrison C; Otterson GA; Plass C
J Natl Cancer Inst; 2006 Mar; 98(6):396-406. PubMed ID: 16537832
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of pre B cell leukemia transcription factor 2 (PBX2) expression in non-small cell lung carcinoma.
Qiu Y; Morii E; Tomita Y; Zhang B; Matsumura A; Kitaichi M; Okumura M; Aozasa K
Cancer Sci; 2009 Jul; 100(7):1198-209. PubMed ID: 19356220
[TBL] [Abstract][Full Text] [Related]
20. Molecular Changes Associated with Acquired Resistance to Crizotinib in ROS1-Rearranged Non-Small Cell Lung Cancer.
Song A; Kim TM; Kim DW; Kim S; Keam B; Lee SH; Heo DS
Clin Cancer Res; 2015 May; 21(10):2379-87. PubMed ID: 25688157
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
